<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829657</url>
  </required_header>
  <id_info>
    <org_study_id>0170</org_study_id>
    <secondary_id>2018-003941-41</secondary_id>
    <nct_id>NCT03829657</nct_id>
  </id_info>
  <brief_title>Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure</brief_title>
  <acronym>REDWOOD</acronym>
  <official_title>A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating&#xD;
      Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, multi-center, randomized withdrawal study to evaluate the sustained benefit in&#xD;
      efficacy and safety of ampreloxetine in subjects with primary autonomic failures (MSA, PD, or&#xD;
      PAF) and symptomatic nOH. The study consists of 3 periods: (i) 16-week open-label (OL)&#xD;
      treatment with ampreloxetine, (ii) 6-week randomized placebo-controlled treatment, and (iii)&#xD;
      2-week follow-up (only for patients who do not enroll in Study 0171 (long-term extension&#xD;
      safety study)).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open Label Extension followed by Randomized Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (worsening) from baseline in OHSA#1 score of 1.0 point and worsening of disease severity as assessed by a 1 point change in PGI-S</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>Score change from baseline on Question 1 of the Orthostatic Hypotension Symptom Assessment (OHSA). Question #1 assesses dizziness, lightheadedness, feeling faint, or feeling like you might blackout and Score change from baseline on Patient Global Impression of Severity (PGI-S). PGI-S assesses patient's impression of disease severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OHSA#1 at Week 6 post randomization at Week 6 post randomization.</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>Score change from baseline on Question 1 of the Orthostatic Hypotension Symptom Assessment (OHSA). Question #1 assesses dizziness, lightheadedness, feeling faint, or feeling like you might blackout.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OHSA composite score at Week 6 post randomization</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>Orthostatic Hypotension Symptom Assessment (OHSA) is an assessment of the severity of symptoms from low blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OHDAS composite score at Week 6 post randomization</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>Orthostatic Hypotension Daily Activities Scale (OHDAS) is an assessment of how low blood pressure symptoms affect daily life.&#xD;
OHDAS is a 4 item assessment that uses an 11 point scale from 0 to 10, with 0 indicating no symptoms/no interference and 10 indicating the worst possible symptoms/complete interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PGI-S at Week 6 post randomization</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>Score change from baseline on Patient Global Impression of Severity (PGI-S). PGI-S assesses patient's impression of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent of time spent in standing position as measured by a wearable device at Week 6 post randomization</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>A wearable device, such as an activity monitor, that provides date- and time-stamped activity information will be used to collect raw motion data to measure the time spent in supine, sitting, and standing positions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average number of steps taken as measured by a wearable device at Week 6 post randomization</measure>
    <time_frame>6-week randomized withdrawal period (Week 16 to Week 22)</time_frame>
    <description>A wearable device, such as an activity monitor, that provides date- and time-stamped activity information will be used to collect raw motion data to measure the time spent in supine, sitting, and standing positions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Symptomatic Neurogenic Orthostatic Hypotension</condition>
  <condition>MSA</condition>
  <condition>Parkinson's Disease (PD)</condition>
  <condition>Pure Autonomic Failure (PAF)</condition>
  <arm_group>
    <arm_group_label>ampreloxetine (Open Label (OL))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ampreloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ampreloxetine</intervention_name>
    <description>Oral tablet, QD (Daily)</description>
    <arm_group_label>ampreloxetine</arm_group_label>
    <arm_group_label>ampreloxetine (Open Label (OL))</arm_group_label>
    <other_name>TD-9855</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet, QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (For 0169 Completers Group):&#xD;
&#xD;
          -  Subject has completed 4 weeks of double blind treatment in Study 0169 (V6) and, in the&#xD;
             opinion of the Investigator, could benefit from continued treatment with&#xD;
             ampreloxetine. No minimum score of OHSA#1 is required to enter V1 of Study 0170.&#xD;
&#xD;
          -  Subject has a minimum of 80% study medication compliance in Study 0169.&#xD;
&#xD;
        Inclusion Criteria (For De Novo Group):&#xD;
&#xD;
          -  Subject is male or female and at least 30 years old.&#xD;
&#xD;
          -  Subject must meet the diagnostic criteria of symptomatic nOH, as demonstrated by a&#xD;
             sustained reduction in BP of ≥20 mm Hg (systolic) or ≥10 mm Hg (diastolic) within 3&#xD;
             min of being tilted-up ≥60o from a supine position as determined by a tilt-table test.&#xD;
&#xD;
          -  Subject must score at least a 4 on the OHSA#1 at V1.&#xD;
&#xD;
          -  For subjects with PD only: Subject has a diagnosis of PD according to the United&#xD;
             Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria (1992).&#xD;
&#xD;
          -  For subjects with MSA only: Subject has a diagnosis of possible or probable MSA of the&#xD;
             Parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to The Gilman&#xD;
             Criteria (2008).&#xD;
&#xD;
          -  For subjects with PAF only: Subject has documented impaired autonomic reflexes,&#xD;
             including the Valsalva maneuver performed within 24 months from the date of&#xD;
             randomization&#xD;
&#xD;
          -  Subject has plasma Norepinephrine (NE) levels ≥ 100 pg/mL after being in seated&#xD;
             position for 30 minutes.&#xD;
&#xD;
        Exclusion Criteria (For 0169 Completers Group):&#xD;
&#xD;
          -  Subject has a medical, laboratory, or surgical issue(s) deemed by the investigator to&#xD;
             be clinically significant.&#xD;
&#xD;
          -  Subject has an uncooperative attitude or reasonable likelihood of non-compliance with&#xD;
             the protocol.&#xD;
&#xD;
          -  Subject has a concurrent disease or condition that, in the opinion of the&#xD;
             investigator, would confound or interfere with study participation or evaluation of&#xD;
             safety, tolerability, or pharmacokinetics of the study drug.&#xD;
&#xD;
        Exclusion Criteria (For De Novo Group):&#xD;
&#xD;
          -  Subject has a known systemic illness known to produce autonomic neuropathy, including&#xD;
             but not limited to amyloidosis, and autoimmune neuropathies.&#xD;
&#xD;
          -  Subject has a known intolerance to other NRIs or serotonin norepinephrine reuptake&#xD;
             inhibitors (SNRIs).&#xD;
&#xD;
          -  Subject currently uses concomitant antihypertensive medication for the treatment of&#xD;
             essential hypertension unrelated to autonomic dysfunction.&#xD;
&#xD;
          -  Subject has used strong CYP1A2 inhibitors or inducers within 7 days or 5 half-lives,&#xD;
             whichever is longer, prior to V1 or requires concomitant use until the follow-up&#xD;
             visit.&#xD;
&#xD;
          -  Subject has changed dose, frequency, or type of prescribed medication for orthostatic&#xD;
             hypotension within 7 days prior to V1.&#xD;
&#xD;
               -  Midodrine and droxidopa (if applicable) must be tapered off at least 7 days prior&#xD;
                  to V1.&#xD;
&#xD;
          -  Subject has known or suspected alcohol or substance abuse within the past 12 months&#xD;
             (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision&#xD;
             [DSM-IV-TR®] definition of alcohol or substance abuse).&#xD;
&#xD;
          -  Subject has a clinically unstable coronary artery disease, or has had a major&#xD;
             cardiovascular or neurological event in the past 6 months.&#xD;
&#xD;
          -  Subject has used any monoamine oxidase inhibitor (MAO-I) within 14 days prior to V1.&#xD;
&#xD;
          -  Subject has a history of untreated closed angle glaucoma, or treated closed angle&#xD;
             glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk&#xD;
             to the subject.&#xD;
&#xD;
          -  Subject has any significant uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          -  Subject has a Montreal Cognitive Assessment (MoCA) ≤23.&#xD;
&#xD;
          -  Subject is unable or unwilling to complete all protocol specified procedures including&#xD;
             questionnaires.&#xD;
&#xD;
          -  Subject had a myocardial infarction in the past 6 months or has current unstable&#xD;
             angina.&#xD;
&#xD;
          -  Subject has known congestive heart failure (New York Heart Association [NYHA] Class 3&#xD;
             or 4).&#xD;
&#xD;
          -  Subject has a clinically significant abnormal laboratory finding (e.g., alanine&#xD;
             aminotransferase [ALT] or aspartate aminotransferase [AST] &gt;3.0 x upper limit of&#xD;
             normal [ULN]; blood bilirubin [total] &gt;1.5 x ULN; estimated glomerular filtration rate&#xD;
             (eGFR) &lt;30 mL/min/1.73 m2, or any abnormal laboratory value that could interfere with&#xD;
             safety of the subject).&#xD;
&#xD;
          -  Subject has demonstrated a history of lifetime suicidal ideation and/or suicidal&#xD;
             behavior, as outlined by the Columbia Suicide Severity Rating Scale&#xD;
             (C-SSRS)(Baseline/Screening Version). Subject should be assessed by the rater for risk&#xD;
             of suicide and the subject's appropriateness for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Movement Disorder Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Neuroscience Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Neurological Associates, PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SFM Clinical Research, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies, Inc</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center (UCGNI)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ineba - Instituto de Neurociencias de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1192AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Médico de la Policía Federal Argentina Churruca Visca</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C14375CP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research</name>
      <address>
        <city>Cuidad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Hospital, Neurosciences Department</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>02139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Centre, Level 3 Monash Health Translational Precinct Building Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital Neurology Department</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perron Institute for Neurological and Translational Science</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck, Abteilung fur Neurologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tulln Abteilung fur Neurologie</name>
      <address>
        <city>Tulln</city>
        <zip>3430</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHATNP Sv. Naum EAD Clinic of Neurological Diseases for Locomotor Disorders</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Teaching Research and Wellness Building</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astra Team Clinic</name>
      <address>
        <city>Tallinn</city>
        <zip>11315</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow-Klinikum, Klinik fur Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Christian Oehlwein</name>
      <address>
        <city>Gera</city>
        <zip>7551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, Neurologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Campus</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna-Clinica Neurologica - Dipt di Scienze Neurologiche Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico - Vittorio Emanuele (Presidio Gaspare Rodolico)</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli studi Gabriele D' Annunzio Chieti</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana- Ospedale S. Chiara, U.O. di Neurologia - Neurofisiopatologia</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV - Policlinico Tor Vergata I U.0.C. Neurologia</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS / Istituto di Neurologia - Ambulatorio Disturbi del Movimento</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU San Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Zealand Brain Research Institute</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska, Prof. Grzegorz Opala</name>
      <address>
        <city>Katowice</city>
        <zip>40-588</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp. Zo.o. Centrum Neurologii Klinicznej</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Zdrowia dr Boczarska-Jedynak</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO-CARE Sp. z o.o. Sp. Komandytowa</name>
      <address>
        <city>Siemianowice Śląskie</city>
        <zip>41-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Senhora da Oliveira Guimarães</name>
      <address>
        <city>Guimarães</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS-Campus Neurologico Senior</name>
      <address>
        <city>Torres Vedras</city>
        <zip>2560-280</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Institution of Healthcare City Hospital #40 of Kurortnyi Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sestroretsk</state>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital #34</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Neurological Center Sibneiromed, LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI National Medical Research Centre of psychiatry and neurology named after V.M. Bekhterev of the MOH of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI of Science Institute of Human Brain named after N .P. Bekhtereva of Russian Academy of Sciences</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Mutua de Terrasa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise City Policlinic #9 of Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <zip>61172</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise of Lviv Regional Council Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital NHS Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognition Health Unit 2</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre, William Harvey Heart Centre</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health Ltd</name>
      <address>
        <city>London</city>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://redwood-study.com/</url>
    <description>Click on the link to see if you qualify to participate</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic Neurogenic Orthostatic Hypotension</keyword>
  <keyword>symptomatic nOH</keyword>
  <keyword>multiple symptom atrophy</keyword>
  <keyword>MSA</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>PD</keyword>
  <keyword>pure autonomic failure</keyword>
  <keyword>PAF</keyword>
  <keyword>orthostatic hypotension</keyword>
  <keyword>OH</keyword>
  <keyword>REDWOOD</keyword>
  <keyword>ampreloxetine</keyword>
  <keyword>low blood pressure</keyword>
  <keyword>dizziness</keyword>
  <keyword>fainting</keyword>
  <keyword>blacking out</keyword>
  <keyword>lightheadedness</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>hypotension</keyword>
  <keyword>Neurogenic Orthostatic Hypotension</keyword>
  <keyword>nOH</keyword>
  <keyword>170</keyword>
  <keyword>0170</keyword>
  <keyword>145</keyword>
  <keyword>0145</keyword>
  <keyword>TD-9855</keyword>
  <keyword>TD9855</keyword>
  <keyword>Parkinsonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

